Ping-Hsien Lee

Ping-Hsien Lee is a Senior Scientist at AstraZeneca since November 2020, with prior experience as a Staff Scientist at Children's National Health System, where development of SARS-CoV-2-specific T cell products and CRISPR-Cas9 gene editing platforms were key accomplishments. A Visiting Fellow at the National Institutes of Health from April 2014 to March 2019, significant work involved understanding IL-1b's role in enhancing T cell function and engineering T cells for improved anti-tumor efficacy. Graduate studies at Baylor College of Medicine focused on transcription factors influencing T cell differentiation and myeloid dendritic cell development. Educational background includes a Ph.D. in Immunology from Baylor College of Medicine, an MS from National Taiwan University, and a BS in Medical Technology from National Taiwan University. Research experience began as a Research Assistant at Academia Sinica.